Curaleaf shares down 8% after FDA sends warning letter over CBD health claims
Cannabis Law Report
JULY 24, 2019
Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Full report at. Full Letter. Source: [link].
Let's personalize your content